SME Times is powered by   
Search News
Just in:   • RBI clarifies forex rules for services exports and imports  • Govt encourages industry to boost India's domestic, overseas mineral supply chains  • Trump cites India's growth to press Fed on rates  • FIIs pump Rs 1,11,950 crore into Indian stock markets this month to date  • India poised for big leap in AI, semiconductor manufacturing 
Last updated: 27 Sep, 2014  

thomson-reuter.Thmb.jpg Thomson Reuters launches the Outpartnering Registry

thomson-reuter.jpg
   Top Stories
» FIIs pump Rs 1,11,950 crore into Indian stock markets this month to date
» Sensex jumps 898 points, Nifty closes above 25,800 as banks rally on return of foreign inflows
» Microsoft rolls out agentic AI tools, Copilot Workspaces at Ignite conference
» Nifty hits 9-month high, Bank Nifty scales record peak as market rally extends
» India-Egypt trade has potential to scale $35 billion by 2035: Assocham
PR Newswire | 21 Jun, 2010
PHILADELPHIA and LONDON: Thomson Reuters announced today that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around the world.

The Outpartnering Registry is available free to all organizations with drugs in development. It enables authorized users to share essential information about their company and drug pipeline with potential partners. Ninety percent of the world's top 50 pharmaceutical companies will have access to information in the registry via Thomson Pharma® Partnering, the leading source of pipeline intelligence.

The Outpartnering Registry allows organizations to:

    * Indicate which of their programs and drugs are available for partnering and, optionally, what type of partnership they are seeking in which regions of the world.
    * Add and update partnering contacts together with links to LinkedIn profiles.
    * Display attendance at partnering conferences and increase networking opportunities.


"Pharma companies need new and innovative ways to share the financial risk of developing drugs," said Mark Gordon, director of product strategy at Thomson Reuters. "This new initiative benefits both drug innovators, who can easily update their partnering information online, as well as in-licensors, who can quickly find assets available for partnering."

"The Outpartnering Registry from Thomson Reuters will make it easier for us to market products for our clients," said Damon Bowe, consultant at New Orleans BioInnovation Center. "The industry has expressed the need for this registry and it is an effective way for us to market inventions and to create partnerships between academia and industry."

For more information about The Outpartnering Registry, please visit: http://go.thomsonreuters.com/outpartnering

For more information about Thomson Pharma Partnering, please visit: http://go.thomsonreuters.com/partnering

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹96.5
₹94.8
UK Pound
₹132.25
₹128.15
Euro
₹113.6
₹109.8
Japanese Yen ₹61.3 ₹59.45
As on 03 Sep, 2026
  Daily Poll
What’s your biggest challenge with the 45-day payment rule?
 Corporates canceling our orders
 Clients demanding longer credit anyway
 Strained business relationships
 Filing complaints kills future work
 No issues, cash flow has improved
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter